Stockreport

GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

GeneDx Holdings Corp. - Class A  (WGS) 
PDF Expects full year 2025 revenues of $427 million, with exome and genome revenue up 54% (58% excluding a one-time 2024 benefit)Expects fourth quarter 2025 revenues of $121 [Read more]